France · Question · Question écrite
30436
Question 30436 — pharmacy and medications
Introduced
—
Last action
—
Status
posée
Sponsors
—
Subjects
Discovery layer
Source updated
—
Summary
Ms. Pascale Boyer draws the attention of the Minister of Solidarity and Health to the situation of patients suffering from primary immune deficiencies (PID) in these times of health crisis. Primary immunodeficiencies (PID) are rare genetic diseases of the immune system that affect children and adults alike: their daily life with PID means exposure to severe and repeated infections that can lead to their health at stake. The majority of patients receive a vital medication throughout their lives, immunoglobulins (Ig), made from human plasma. They have no therapeutic alternative. Frequent tensions over the supply of Ig have led public authorities to put in place a prioritization of indications for prescribing Ig, to ensure access to their treatment for patients without an alternative. therapeutic in case of tension. The global health context of covid-19 has exacerbated this threat which is constantly exerted on the patients of the IRIS association, in particular because medicines derived from plasma are in global tension, and because they depend massively on plasma collected in the United States and in some countries of the European Union. Igs are biological drugs for which preparations differ (process manufacturing, origin of plasma, concentration, adjuvants, intravenous (IVIG) or subcutaneous (SCIG) form) meeting the needs of patients (tolerance, method of administration, lifestyle, continuity of treatment). A plurality of actors is therefore necessary to cover the diversity of needs and to ensure regular supply. The French fractionation and biotechnology laboratory (LFB) ensures the development of IVIG in France, but for the reasons mentioned above, this offer alone cannot cover the needs in France. In this regard, she asks him what his intentions are to promote a proactive approach, centered on the needs of patients, aimed at combating the structural obstacles to the adequate and continuous supply of Ig, in order to secure the treatment of patients with PID throughout their lives.
Machine translation from French. The official text remains authoritative.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.assemblee-nationale.fr/dyn/15/questions/QANR5L15QE30436
- Open data entity: https://www.assemblee-nationale.fr/dyn/opendata/QANR5L15QE30436